Foghorn Therapeutics (FHTX) Net Income towards Common Stockholders (QoQ) (2019 - 2026)
Foghorn Therapeutics (FHTX) Net Income towards Common Stockholders (QoQ) (2019 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - |
| 10 | Foghorn Therapeutics | 362.65 Mn | 273.74 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -238.14% |
| Dec 31, 2025 | 42.88% |
| Sep 30, 2025 | 47.67% |
| Jun 30, 2025 | -247.16% |
| Mar 31, 2025 | -17.84% |
| Dec 31, 2024 | -1.99% |
| Sep 30, 2024 | 16.78% |
| Jun 30, 2024 | 8.14% |
| Mar 31, 2024 | -3.77% |
| Dec 31, 2023 | -68.04% |
| Sep 30, 2023 | 51.35% |
| Jun 30, 2023 | 3.28% |
| Mar 31, 2023 | -5.55% |
| Dec 31, 2022 | -12.10% |
| Sep 30, 2022 | 5.65% |
| Jun 30, 2022 | -1.48% |
| Mar 31, 2022 | 26.47% |
| Dec 31, 2021 | 63.52% |
| Sep 30, 2021 | -0.53% |
| Jun 30, 2021 | -291.33% |